ES2104845T3 - Composiciones lipofilas de sales de antibioticos oligosacaridos. - Google Patents

Composiciones lipofilas de sales de antibioticos oligosacaridos.

Info

Publication number
ES2104845T3
ES2104845T3 ES92309368T ES92309368T ES2104845T3 ES 2104845 T3 ES2104845 T3 ES 2104845T3 ES 92309368 T ES92309368 T ES 92309368T ES 92309368 T ES92309368 T ES 92309368T ES 2104845 T3 ES2104845 T3 ES 2104845T3
Authority
ES
Spain
Prior art keywords
formula
antibiotic
amount
lipophyl
oligosaccharid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309368T
Other languages
English (en)
Spanish (es)
Inventor
Mahesh Patel
Vincent P Gullo
Roberta Hare
David Loebenberg
James B Morton
George H Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2104845T3 publication Critical patent/ES2104845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
ES92309368T 1991-10-16 1992-10-14 Composiciones lipofilas de sales de antibioticos oligosacaridos. Expired - Lifetime ES2104845T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77786491A 1991-10-16 1991-10-16

Publications (1)

Publication Number Publication Date
ES2104845T3 true ES2104845T3 (es) 1997-10-16

Family

ID=25111545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309368T Expired - Lifetime ES2104845T3 (es) 1991-10-16 1992-10-14 Composiciones lipofilas de sales de antibioticos oligosacaridos.

Country Status (27)

Country Link
US (1) US5624914A (en:Method)
EP (2) EP0610295A1 (en:Method)
JP (1) JP2614407B2 (en:Method)
KR (1) KR100249584B1 (en:Method)
CN (1) CN1035923C (en:Method)
AT (1) ATE156019T1 (en:Method)
AU (1) AU678344B2 (en:Method)
CA (1) CA2121345C (en:Method)
DE (1) DE69221252T2 (en:Method)
DK (1) DK0538011T3 (en:Method)
ES (1) ES2104845T3 (en:Method)
FI (1) FI941723A0 (en:Method)
GR (1) GR3024800T3 (en:Method)
HK (1) HK1001085A1 (en:Method)
HR (1) HRP921069B1 (en:Method)
HU (1) HUT75157A (en:Method)
IL (1) IL103446A (en:Method)
MX (1) MX9205922A (en:Method)
NO (1) NO307326B1 (en:Method)
NZ (1) NZ244735A (en:Method)
PH (1) PH31675A (en:Method)
PL (1) PL170591B1 (en:Method)
SI (1) SI9200260A (en:Method)
TW (1) TW221378B (en:Method)
WO (1) WO1993007904A1 (en:Method)
YU (1) YU48722B (en:Method)
ZA (1) ZA927923B (en:Method)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948688A (en) * 1991-10-16 1999-09-07 Schering Corporation Method of determining monomeric drug content
US6380172B1 (en) 1991-10-16 2002-04-30 Schering Corporation Monomeric lipophilic oligosaccharide antibiotic compositions
US5652226A (en) * 1995-12-22 1997-07-29 Schering Corporation Water soluble antibiotics
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5763600A (en) * 1997-04-18 1998-06-09 Schering Corporation Oligosaccharide antibiotics and process for preparation thereof
CA2305599A1 (en) * 1997-10-03 1999-04-15 Galenica Pharmaceuticals, Inc. Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
US6162910A (en) * 1998-11-30 2000-12-19 Schering Corporation Process for preparing lipophilic oligosaccharide antibiotics
WO2000037670A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
US6320044B1 (en) 1998-12-18 2001-11-20 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
WO2001039573A2 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von lungensurfactant zur behandlung von legionärskrankheit
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
SI1278549T1 (sl) * 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
DE10109166A1 (de) * 2001-02-25 2002-09-12 Combinature Biopharm Ag Avilamycin-Derivate
BRPI0508854A (pt) * 2004-03-17 2007-08-28 Panacos Pharmaceuticals Inc sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico
EP1987935A3 (en) * 2004-12-01 2008-11-19 Nitto Denko Corporation Foam Filling Member
JP2008535923A (ja) * 2005-04-12 2008-09-04 パナコス ファーマシューティカルズ インコーポレーティッド 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸ジ−n−メチル−d−グルカミンの多形
MX2010002815A (es) * 2007-09-14 2010-07-30 Sanofi Pasteur Biologics Co Composiciones farmaceuticas que contienen toxoides a y b de clostridium difficile.
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
EP2663338B1 (en) * 2011-01-14 2024-03-06 Emory University Glucose-based oligosaccharides comprising a positron-emitting radionuclide and their use for imaging
EA033892B1 (ru) 2015-06-10 2019-12-05 Втесс, Инк. Композиции гидроксипропил-бета-циклодекстринов и способы
CN106317143B (zh) * 2016-08-23 2020-10-30 河北圣雪大成制药有限责任公司 一种提取阿维拉霉素的方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
CN117024611B (zh) * 2023-03-01 2024-05-17 中国科学院南海海洋研究所 寡糖类抗生素everninomicin高产菌株的构建及活性的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR128F (en:Method) * 1962-04-02
US3915956A (en) * 1973-07-09 1975-10-28 Schering Corp Reduction products of everninomicins and methods for their manufacture
US3920629A (en) * 1973-09-19 1975-11-18 Schering Corp Desevernitrose everninomicins and method for their manufacture
US4006225A (en) * 1973-10-31 1977-02-01 Schering Corporation Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor
US4027016A (en) * 1976-01-19 1977-05-31 Schering Corporation Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor
US3998708A (en) * 1976-01-19 1976-12-21 Schering Corporation Electrochemical process for preparing hydroxylaminoeverninomicins
US4129720A (en) * 1977-02-14 1978-12-12 Schering Corporation Aminoeverninomicin and derivatives thereof
US4597968A (en) * 1982-08-06 1986-07-01 Schering Corporation Antibiotic 13-384 complex from Micromonospora carbonacea var africana
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4735903A (en) * 1984-06-21 1988-04-05 Schering Corporation Micromonospora carbonacea var africana
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4767748A (en) * 1985-10-15 1988-07-30 Schering Corporation Substituted oligosaccharide antibodies
US4622314A (en) * 1985-10-15 1986-11-11 Schering Corporation Substituted oligosaccharide antibiotics
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
AU2780692A (en) 1993-05-21
NO941276L (no) 1994-04-08
EP0538011A1 (en) 1993-04-21
CN1035923C (zh) 1997-09-24
FI941723A7 (fi) 1994-04-14
PH31675A (en) 1999-01-18
EP0538011B1 (en) 1997-07-30
SI9200260A (en) 1993-06-30
CN1073359A (zh) 1993-06-23
GR3024800T3 (en) 1998-01-30
DE69221252D1 (de) 1997-09-04
EP0610295A1 (en) 1994-08-17
HRP921069A2 (en) 1994-12-31
DE69221252T2 (de) 1998-01-22
FI941723A0 (fi) 1994-04-14
DK0538011T3 (da) 1997-09-08
KR100249584B1 (ko) 2000-04-01
HRP921069B1 (en) 1999-12-31
HK1001085A1 (en) 1998-05-22
YU48722B (sh) 1999-07-28
YU92192A (sr) 1996-01-09
HU9401104D0 (en) 1994-07-28
IL103446A0 (en) 1993-03-15
JP2614407B2 (ja) 1997-05-28
HUT75157A (en) 1997-04-28
WO1993007904A1 (en) 1993-04-29
ZA927923B (en) 1993-04-26
CA2121345C (en) 1998-08-25
PL170591B1 (pl) 1997-01-31
AU678344B2 (en) 1997-05-29
NO307326B1 (no) 2000-03-20
CA2121345A1 (en) 1993-04-29
NO941276D0 (no) 1994-04-08
JPH06510546A (ja) 1994-11-24
IL103446A (en) 1997-02-18
MX9205922A (es) 1994-08-31
US5624914A (en) 1997-04-29
NZ244735A (en) 1995-12-21
ATE156019T1 (de) 1997-08-15
TW221378B (en:Method) 1994-03-01

Similar Documents

Publication Publication Date Title
ES2104845T3 (es) Composiciones lipofilas de sales de antibioticos oligosacaridos.
FI950166A0 (fi) Uudet farmaseuttiset koostumukset
CA2221190A1 (en) Novel substituted taxanes and pharmaceutical compositions containing them
ATE55900T1 (de) Feste pharmazeutische formulierungen mit ueber einen weiten bereich variablen langsamen freigabe nullter ordnung durch kontrollierte oberflaechenerosion.
GB1107093A (en) Phenyl aliphatic acids and their salts and esters
ES2036580T3 (es) Composiciones quimicas y su uso como aditivos a combustibles.
ES8304534A1 (es) "procedimiento de preparacion de derivados de 1-fenil-1-hidroxi-etilamina".
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR008540A1 (es) Composiciones antibioticas de oligosacaridos lipofilicos, composiciones farmaceuticas que los contienen y el uso de dichas composiciones para prepararmedicamentos.
ES346057A1 (es) Procedimiento para la obtencion de 3,4-dihidroxifenilalca- nolaminas.
AR019190A1 (es) Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
SE8204918D0 (sv) Nya 3-amino-pregn-5-en-derivat, deras salter, sett for framstellning och anvendning derav som lekemedel och kompositioner innehallande dem
GR3006746T3 (en:Method)
JPS5492951A (en) Novel aminoglycoside derivative
AR008234A1 (es) Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento
ES2064754T3 (es) Pasta dental inhibidora de los depositos.
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
AR026726A1 (es) Nuevos compuestos antitromboticos y composiciones farmaceuticas que los contienen
RU99102690A (ru) Композиции синтетического мыльного бруса с улучшенной способностью к обработке, содержащие амфотерные поверхностно-активные вещества, основанные на минимальных количествах мыла жирной кислоты и минимальных отношениях мыла насыщенной кислоты к мылу ненасыщенной кислоты
CO4771112A1 (es) Pasta/barra de platos transparente
ES2053880T3 (es) Utilizacion de derivados de adenosina en la preparacion de composiciones farmaceuticas que poseen actividad inmunoestimulante.
ATE150967T1 (de) Wirkstoffe gegen fettleibigkeit
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
GB1364521A (en) Aminoglycoside antibiotics

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 538011

Country of ref document: ES